 |
|
First biomarker discovered that predicts prostate cancer outcome
August 15, 2007ROCHESTER, Minn. -- Mayo Clinic researchers have identified the first immune molecule that appears to play a role in prostate cancer development and in predicting cancer recurrence and progression after surgery. The report on the B7-H3 molecule by Mayo Clinic Cancer Center appears today in Cancer Research.
"This discovery will allow physicians to individualize treatment and observation plans for prostate cancer patients," says Timothy Roth, M.D., a Mayo Clinic urology resident and lead author of the study. "Being able to tell a patient his specific risk after surgery, and perhaps even prior to surgery, will be a huge step forward."
Until now there were no strongly-predictive molecules for prostate cancer. The most notable other prostate biomarkers, prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA) are useful to diagnose prostate cancer. However, PSA tends to leave prostate cancer cells and migrate throughout the body, making it a poor target for therapy.
Today's Research
In this study, Mayo researchers demonstrate that nearly all normal, pre-malignant and cancerous prostate cells have B7-H3 on their surface. Unlike PSA, B7-H3 stays attached to the surface of prostate cancer cells and does not appear to migrate, thus making B7-H3 a particularly attractive target for therapy. The researchers believe that B7-H3 kills or paralyzes immune cells that are trying to attack the cancer. Their findings indicate that B7-H3 may prove useful as a diagnostic, prognostic and even therapeutic tool because it is stably or increasingly displayed by tumor cells as prostate cancers develop -- even after initiation of anti-hormone therapy, which is the most common treatment for advanced prostate cancer.
The physician-research team examined tissue from 338 consecutive patients who had cancers confined to the prostate and were treated exclusively with a radical prostatectomy (surgery to remove the prostate) between 1995 and 1998. All tumors and precancerous tissues displayed B7-H3, but patients with the highest levels of B7-H3 within their prostate tumors (19.8 percent) were four times more likely to experience cancer progression compared to those with weak levels of B7-H3 within their tumors. Moderate levels of B7-H3 also correlated with a slightly higher risk of recurrence (35 percent).
"Because B7-H3 is present in all prostate cancer tumors, and marked levels predict recurrence, we are able to forecast with much greater certainty the likelihood of cancer progression, regardless of therapeutic intervention," says Eugene Kwon, M.D., a senior investigator and urologist at Mayo Clinic.
For some patients, a 'watchful waiting' clinical approach is sometimes used to manage prostate cancer prior to resorting to therapy to see if the cancer becomes increasingly aggressive. The researchers say that the evaluation of B7-H3 levels in prostate biopsies from patients may soon help to determine which patients may benefit from a watchful waiting strategy versus early aggressive treatment.
Individualized Medicine Emerges
Mayo Clinic's findings on biomarker identification may accelerate the development of new forms of therapy, say the researchers. Additionally, prostate cancer now joins kidney cancer as a malignancy that can be tracked and predicted based on the presence of B7-H immune molecules.
"This is the way of the future," says Dr. Kwon, "We are becoming educated about ways to flesh out the molecular signatures of each patient's cancer. Using such molecular signatures will facilitate, for the first time, a truly individualized approach to prescribing the most appropriate therapy for a given patient. We will soon be able to tailor-make therapies for each person's cancer."
B7-H3 in the Future
To understand how B7-H3 affects the immune system, and whether a mutation of B7-H3 is involved in the anti-immune activity, more research is necessary. Mayo is planning clinical trials for a number of cancers in late 2008, and researchers are currently developing the necessary therapeutic antibodies to be used in these studies. Investigators expect that clinical laboratory tests for the B7-H proteins may become available at Mayo to assist with the assessment of patients with kidney cancer by late 2007 or early 2008, and then for prostate cancer patients shortly thereafter.
Unique Mayo Registry Key
This study was possible because of Mayo's unique patient registry for prostate cancer. The registry contains hundreds of discrete pieces of information, ranging from environmental factors to specific medical test results, for more than 15,000 prostate cancer patients, all followed prospectively since the first patient was entered into the database in 1970. The Mayo Clinic prostate cancer and kidney cancer registries represent the most detailed and complete cancer reference tools in the world. Using the latter registry, Mayo investigators were previously able to link high levels of another B7-H molecule, B7-H1, to poor kidney cancer outcomes, including significantly shortened survival times.
Without the key road maps provided by these registries, the recognition of important molecules that drive cancer would not be feasible, say the researchers. Use of these patient registries enables laboratory science to be directly linked to patient care and survival following treatment.
"To a large extent, working with these registries dramatically lessens the time, resources and effort that are required to link a candidate molecule to its role in cancer development and progression," says Dr. Kwon, who is also the co-director of the Cancer Immunology and Immunotherapy Program in Mayo Clinic Cancer Center. "Our studies are the very first to provide a clear link between immune molecules and the behaviors of various cancers."
Dr. Kwon and his fellow researchers have been charged by Mayo Clinic to investigate all cancers for immune molecules that may govern cancer behavior while doubling as new therapeutic targets -- identifying future research targets.
Background: B7-H3 and Immunology Research at Mayo
Mayo Clinic Cancer Center was the first to discover the B7-H family of immune molecules -- proteins that normally help regulate the immune response process. Mayo investigators showed that B7-H3 and other members of the B7-H family, such as B7-H1, can have an inhibitory function and actually protect cancers as they develop.
Mayo Clinic identified B7-H3 as a new molecule in 2001. Mayo researchers published the first research identifying an immune molecule's role in cancer, with multiple publications pertaining to the role of B7-H1 in heralding a poor prognosis for patients with kidney cancer. Although a number of hypotheses predicted that these molecules might enable cancer development, no one had shown it clinically prior to these studies.
Thus far, the investigators have spent significant time researching the B7-H family of molecules. They have reviewed tens of thousands of samples from at least 30 different cancers, including cancers of the breast, colon, pancreas, brain and ovary, as well as mesothelioma.
Mayo Clinic
Today's Research
In this study, Mayo researchers demonstrate that nearly all normal, pre-malignant and cancerous prostate cells have B7-H3 on their surface. Unlike PSA, B7-H3 stays attached to the surface of prostate cancer cells and does not appear to migrate, thus making B7-H3 a particularly attractive target for therapy. The researchers believe that B7-H3 kills or paralyzes immune cells that are trying to attack the cancer. Their findings indicate that B7-H3 may prove useful as a diagnostic, prognostic and even therapeutic tool because it is stably or increasingly displayed by tumor cells as prostate cancers develop -- even after initiation of anti-hormone therapy, which is the most common treatment for advanced prostate cancer.
The physician-research team examined tissue from 338 consecutive patients who had cancers confined to the prostate and were treated exclusively with a radical prostatectomy (surgery to remove the prostate) between 1995 and 1998. All tumors and precancerous tissues displayed B7-H3, but patients with the highest levels of B7-H3 within their prostate tumors (19.8 percent) were four times more likely to experience cancer progression compared to those with weak levels of B7-H3 within their tumors. Moderate levels of B7-H3 also correlated with a slightly higher risk of recurrence (35 percent).
"Because B7-H3 is present in all prostate cancer tumors, and marked levels predict recurrence, we are able to forecast with much greater certainty the likelihood of cancer progression, regardless of therapeutic intervention," says Eugene Kwon, M.D., a senior investigator and urologist at Mayo Clinic.
For some patients, a 'watchful waiting' clinical approach is sometimes used to manage prostate cancer prior to resorting to therapy to see if the cancer becomes increasingly aggressive. The researchers say that the evaluation of B7-H3 levels in prostate biopsies from patients may soon help to determine which patients may benefit from a watchful waiting strategy versus early aggressive treatment.
Individualized Medicine Emerges
Mayo Clinic's findings on biomarker identification may accelerate the development of new forms of therapy, say the researchers. Additionally, prostate cancer now joins kidney cancer as a malignancy that can be tracked and predicted based on the presence of B7-H immune molecules.
"This is the way of the future," says Dr. Kwon, "We are becoming educated about ways to flesh out the molecular signatures of each patient's cancer. Using such molecular signatures will facilitate, for the first time, a truly individualized approach to prescribing the most appropriate therapy for a given patient. We will soon be able to tailor-make therapies for each person's cancer."
B7-H3 in the Future
To understand how B7-H3 affects the immune system, and whether a mutation of B7-H3 is involved in the anti-immune activity, more research is necessary. Mayo is planning clinical trials for a number of cancers in late 2008, and researchers are currently developing the necessary therapeutic antibodies to be used in these studies. Investigators expect that clinical laboratory tests for the B7-H proteins may become available at Mayo to assist with the assessment of patients with kidney cancer by late 2007 or early 2008, and then for prostate cancer patients shortly thereafter.
Unique Mayo Registry Key
This study was possible because of Mayo's unique patient registry for prostate cancer. The registry contains hundreds of discrete pieces of information, ranging from environmental factors to specific medical test results, for more than 15,000 prostate cancer patients, all followed prospectively since the first patient was entered into the database in 1970. The Mayo Clinic prostate cancer and kidney cancer registries represent the most detailed and complete cancer reference tools in the world. Using the latter registry, Mayo investigators were previously able to link high levels of another B7-H molecule, B7-H1, to poor kidney cancer outcomes, including significantly shortened survival times.
Without the key road maps provided by these registries, the recognition of important molecules that drive cancer would not be feasible, say the researchers. Use of these patient registries enables laboratory science to be directly linked to patient care and survival following treatment.
"To a large extent, working with these registries dramatically lessens the time, resources and effort that are required to link a candidate molecule to its role in cancer development and progression," says Dr. Kwon, who is also the co-director of the Cancer Immunology and Immunotherapy Program in Mayo Clinic Cancer Center. "Our studies are the very first to provide a clear link between immune molecules and the behaviors of various cancers."
Dr. Kwon and his fellow researchers have been charged by Mayo Clinic to investigate all cancers for immune molecules that may govern cancer behavior while doubling as new therapeutic targets -- identifying future research targets.
Background: B7-H3 and Immunology Research at Mayo
Mayo Clinic Cancer Center was the first to discover the B7-H family of immune molecules -- proteins that normally help regulate the immune response process. Mayo investigators showed that B7-H3 and other members of the B7-H family, such as B7-H1, can have an inhibitory function and actually protect cancers as they develop.
Mayo Clinic identified B7-H3 as a new molecule in 2001. Mayo researchers published the first research identifying an immune molecule's role in cancer, with multiple publications pertaining to the role of B7-H1 in heralding a poor prognosis for patients with kidney cancer. Although a number of hypotheses predicted that these molecules might enable cancer development, no one had shown it clinically prior to these studies.
Thus far, the investigators have spent significant time researching the B7-H family of molecules. They have reviewed tens of thousands of samples from at least 30 different cancers, including cancers of the breast, colon, pancreas, brain and ovary, as well as mesothelioma.
Mayo Clinic
Prostate Cancer News and Current Prostate Cancer Events RSSToo much calcium in blood may increase risk of fatal prostate cancer
Men who have too much calcium in their bloodstreams may have an increased risk of fatal prostate cancer, according to a new analysis from Wake Forest University School of Medicine and the University of Wisconsin.
Height linked to risk of prostate cancer development and progression
A man's height is a modest marker for risk of prostate cancer development, but is more strongly linked to progression of the cancer, say British researchers who conducted their own study on the connection and also reviewed 58 published studies.
Health risk behaviors associated with lower prostate specific antigen awareness
According to a study conducted at Columbia University Mailman School of Public Health, health risk behaviors such as smoking and obesity are associated with lower awareness of the Prostate Specific Antigen (PSA), which could lead to a lower likelihood of undergoing actual prostate cancer screening.
Study shows PDE5 inhibitor more effective when used on demand in erectile dysfunction
European Urology, the official journal of the European Association of Urology will be featuring the article 'Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy' by F. Montorsi et al.in the October issue, showing for the first time that vardenafil, a PDE5 inhibitor, is more efficacious when used on-demand in men with erectile dysfunction, supporting a shift towards on-demand dosing with PDE5 inhibitors in this patient group.
Satisfaction and regret after radical prostatectomy procedures studied
Studies have shown that approximately 16% of patients with localised prostate cancer regret their treatment choice. European Urology, the official journal of the European Association of Urology, will be publishing an article by J.W. Moul et al. comparing differences in satisfaction and regret between patients who underwent open retropubic radical prostatectomy and robot-assisted laparoscopic radical prostatectomy.
State's first single incision robotic kidney removal
For the first time in Michigan, a diseased kidney has been surgically removed at Henry Ford Hospital using highly sophisticated 3D robotics through a single incision.
Anti-tumor effects are enhanced by inhibiting 2 pathways rather than 1
Two independent research groups have found that simultaneous inhibition of two signaling pathways resulted in substantially enhanced antitumor effects in mouse models of prostate and breast cancer. In an accompany commentary, Steven Grant, at Virginia Commonwealth University Health Science Center, Richmond, discusses the clinical importance of these studies and highlights some of the questions that still need to be answered.
Why a common treatment for prostate cancer ultimately fails
Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences.
PSA screening may be biased against obese men, leading to more aggressive cancers
Testing men for elevated levels of prostate-specific antigen (PSA) in the blood -- the gold standard screening test for prostate cancer -- may be biased against obese men, whose PSA levels tend to be deceptively low.
Study finds more PSA screening awareness needed among high-risk groups
In one of the first examinations of PSA screening in younger men, a study published by researchers at Duke Medicine's Prostate Center finds that one-fifth of men under age 50 reported undergoing a prostate specific antigen (PSA) test to detect prostate cancer in the previous year, yet only one in three young black men reported ever having a PSA test in the previous year.
More Prostate Cancer News Articles
 | Dr. Patrick Walsh's Guide to Surviving Prostate Cancer, Second Edition by Patrick C. Walsh, Janet Farrar Worthington EVERY MAN NEEDS THIS BOOK! Each year, more than 200,00 American men are diagnosed with prostate cancer. The good news is that more men are being cured of this disease than ever before. Now in a revised second edition, this lifesaving guide by Dr. Patrick Walsh and ard-winning science writer Janet Farrar Worthington offers a message of hope to every man facing this illness. Prostate cancer is... |
 | You Can Beat Prostate Cancer by Robert J. Marckini The task of choosing the right prostate cancer treatment is daunting. It is further complicated by conflicting information the patient receives from physicians and the Internet. This book is written by a prostate cancer survivor who now runs an international prostate cancer support group. It's about his journey and the important things he learned along the way. It is the book the author wishes... |
 | The Vitamin D Cure by James Dowd, Diane Stafford Groundbreaking new research has traced the source of a wide array of to a single common factor-—vitamin D deficiency. Leading rheumatologist and researcher Dr. James Dowd reveals the causes of vitamin D deficiency and offers a simple, easy-to-follow five-step program that can eliminate or alleviate a host of seemingly incurable conditions, such as arthritis, in as little as six weeks.... |
 | Eat to Beat Prostate Cancer Cookbook by David Ricketts Prostate cancer is now the most common nonskin cancer among men in the United States. In 2005 alone, 250,000 new cases were diagnosed, and that number is certain to rise with each passing year. No one is more aware of this than David Ricketts, experienced cookbook author and recent prostate cancer survivor.Shortly after surgery and radiation treatments, Ricketts began to research food and... |
 | Prostate Health in 90 Days by Larry Clapp Teaches you how to stop prostate trouble in it tracks; understand what causes cancer; reverse the cancer-causing effects; cleanse and strengthen vital organs; enhance your sex life, and virtually eliminate your chance for... |
 | A Primer on Prostate Cancer: The Empowered Patient's Guide by Stephen Strum, Donna L. Pogliano ¡§A Primer on Prostate Cancer, The Empowered Patient¡¦s Guide¡¨ is a basic resource to be used by patients and physicians when there has been a diagnosis of prostate cancer. It outlines a strategy of disease management that is designed to maximize outcomes for the patient and his loved ones. All aspects of diagnosis and testing are discussed; all currently approved treatments for prostate... |
 | The Natural Prostate Cure by Roger Mason This book is the most completely researched book on natural prostate health. It gives you an effective alternative to the usual medical approach of surgery, radion and toxic drugs. Facts elaborate on include medical treatments for BPH often leave men in diapers unable to ever have sex again. Cure yourself of prostate problems safely, effectivelyl andnaturally based on clinical research. You... |
 | Complete Prostate Book: What Every Man Needs to Know by J Stephen Jones For men approaching forty and older, the prostate gland is frequently a source of health problems, ranging from mild nuisances to life-threatening malignancies. Thus, it's important that every man understand what the prostate is, what to do to avoid future problems, and how to treat existing ones. Dr. J. Stephen Jones—a leading urologist at the Cleveland Clinic Foundation and a nationally... |
 | Biopsy Interpretation of the Prostate (Biopsy Interpretation Series) by Jonathan I Epstein, George J Netto The revised Fourth Edition of this highly acclaimed reference is a practical, state-of-the-art, superbly illustrated guide to the evaluation and clinical correlates of prostate biopsy findings. This edition features expanded coverage of mimickers of prostate cancer, a new chapter on immunohistochemistry and molecular techniques, a major update to the Gleason grading system, new information on... |
 | Intimacy With Impotence: The Couple's Guide To Better Sex After Prostate Disease by Ralph Alterowitz, Barbara Alterowitz Erectile dysfunction is a frequent consequence of prostate cancer and other prostate disease treatments. Though unwelcome and embarrassing, it doesn't have to end a couple's sex life. Both informative and practical, Intimacy with Impotence gives couples cause for hope. It discusses impotence in lay terms, provides information on the commercial therapies and medications both available and being... |
| © 2008 BrightSurf.com |